161 related articles for article (PubMed ID: 19814727)
1. Cloning and pharmacological characterization of the dog P2X7 receptor.
Roman S; Cusdin FS; Fonfria E; Goodwin JA; Reeves J; Lappin SC; Chambers L; Walter DS; Clay WC; Michel AD
Br J Pharmacol; 2009 Nov; 158(6):1513-26. PubMed ID: 19814727
[TBL] [Abstract][Full Text] [Related]
2. Cloning and pharmacological characterization of the guinea pig P2X7 receptor orthologue.
Fonfria E; Clay WC; Levy DS; Goodwin JA; Roman S; Smith GD; Condreay JP; Michel AD
Br J Pharmacol; 2008 Feb; 153(3):544-56. PubMed ID: 18037910
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of species-selective P2X(7) receptor antagonists.
Michel AD; Ng SW; Roman S; Clay WC; Dean DK; Walter DS
Br J Pharmacol; 2009 Apr; 156(8):1312-25. PubMed ID: 19309360
[TBL] [Abstract][Full Text] [Related]
4. [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.
Donnelly-Roberts DL; Namovic MT; Surber B; Vaidyanathan SX; Perez-Medrano A; Wang Y; Carroll WA; Jarvis MF
Neuropharmacology; 2009 Jan; 56(1):223-9. PubMed ID: 18602931
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567.
Bhattacharya A; Wang Q; Ao H; Shoblock JR; Lord B; Aluisio L; Fraser I; Nepomuceno D; Neff RA; Welty N; Lovenberg TW; Bonaventure P; Wickenden AD; Letavic MA
Br J Pharmacol; 2013 Oct; 170(3):624-40. PubMed ID: 23889535
[TBL] [Abstract][Full Text] [Related]
6. Agonist potency at P2X7 receptors is modulated by structurally diverse lipids.
Michel AD; Fonfria E
Br J Pharmacol; 2007 Oct; 152(4):523-37. PubMed ID: 17700717
[TBL] [Abstract][Full Text] [Related]
7. Complexities of measuring antagonist potency at P2X(7) receptor orthologs.
Hibell AD; Thompson KM; Xing M; Humphrey PP; Michel AD
J Pharmacol Exp Ther; 2001 Mar; 296(3):947-57. PubMed ID: 11181928
[TBL] [Abstract][Full Text] [Related]
8. Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects.
Michel AD; Clay WC; Ng SW; Roman S; Thompson K; Condreay JP; Hall M; Holbrook J; Livermore D; Senger S
Br J Pharmacol; 2008 Nov; 155(5):738-51. PubMed ID: 18660826
[TBL] [Abstract][Full Text] [Related]
9. Partial agonists and antagonists reveal a second permeability state of human lymphocyte P2Z/P2X7 channel.
Wiley JS; Gargett CE; Zhang W; Snook MB; Jamieson GP
Am J Physiol; 1998 Nov; 275(5):C1224-31. PubMed ID: 9814970
[TBL] [Abstract][Full Text] [Related]
10. The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice.
Honore P; Donnelly-Roberts D; Namovic M; Zhong C; Wade C; Chandran P; Zhu C; Carroll W; Perez-Medrano A; Iwakura Y; Jarvis MF
Behav Brain Res; 2009 Dec; 204(1):77-81. PubMed ID: 19464323
[TBL] [Abstract][Full Text] [Related]
11. Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors.
Donnelly-Roberts DL; Namovic MT; Han P; Jarvis MF
Br J Pharmacol; 2009 Aug; 157(7):1203-14. PubMed ID: 19558545
[TBL] [Abstract][Full Text] [Related]
12. Species and response dependent differences in the effects of MAPK inhibitors on P2X(7) receptor function.
Michel AD; Thompson KM; Simon J; Boyfield I; Fonfria E; Humphrey PP
Br J Pharmacol; 2006 Dec; 149(7):948-57. PubMed ID: 17031382
[TBL] [Abstract][Full Text] [Related]
13. Species- and agonist-dependent differences in the deactivation-kinetics of P2X7 receptors.
Hibell AD; Thompson KM; Simon J; Xing M; Humphrey PP; Michel AD
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jun; 363(6):639-48. PubMed ID: 11414659
[TBL] [Abstract][Full Text] [Related]
14. Negative and positive allosteric modulators of the P2X(7) receptor.
Michel AD; Chambers LJ; Walter DS
Br J Pharmacol; 2008 Feb; 153(4):737-50. PubMed ID: 18071294
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor.
Baraldi PG; del Carmen Nuñez M; Morelli A; Falzoni S; Di Virgilio F; Romagnoli R
J Med Chem; 2003 Apr; 46(8):1318-29. PubMed ID: 12672232
[TBL] [Abstract][Full Text] [Related]
16. Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues.
Humphreys BD; Virginio C; Surprenant A; Rice J; Dubyak GR
Mol Pharmacol; 1998 Jul; 54(1):22-32. PubMed ID: 9658186
[TBL] [Abstract][Full Text] [Related]
17. Cloning and functional characterisation of the mouse P2X7 receptor.
Chessell IP; Simon J; Hibell AD; Michel AD; Barnard EA; Humphrey PP
FEBS Lett; 1998 Nov; 439(1-2):26-30. PubMed ID: 9849870
[TBL] [Abstract][Full Text] [Related]
18. Purinergic receptor modulation of lipopolysaccharide signaling and inducible nitric-oxide synthase expression in RAW 264.7 macrophages.
Hu Y; Fisette PL; Denlinger LC; Guadarrama AG; Sommer JA; Proctor RA; Bertics PJ
J Biol Chem; 1998 Oct; 273(42):27170-5. PubMed ID: 9765236
[TBL] [Abstract][Full Text] [Related]
19. P2X7-related modulation of pathological nociception in rats.
McGaraughty S; Chu KL; Namovic MT; Donnelly-Roberts DL; Harris RR; Zhang XF; Shieh CC; Wismer CT; Zhu CZ; Gauvin DM; Fabiyi AC; Honore P; Gregg RJ; Kort ME; Nelson DW; Carroll WA; Marsh K; Faltynek CR; Jarvis MF
Neuroscience; 2007 Jun; 146(4):1817-28. PubMed ID: 17478048
[TBL] [Abstract][Full Text] [Related]
20. 6-Furopyridine Hexamethylene Amiloride Is a Non-Selective P2X7 Receptor Antagonist.
Cuthbertson P; Elhage A; Al-Rifai D; Sophocleous RA; Turner RJ; Aboelela A; Majed H; Bujaroski RS; Jalilian I; Kelso MJ; Watson D; Buckley BJ; Sluyter R
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
